What is the primary technology behind BullFrog AI?

The core technology is the bfLEAP platform, an analytical engine designed to process multi-modal data. According to slide 7, its key features include feature selection, the ability to make predictions from incomplete data, and 'Explainable AI.' This suggests the platform is built to overcome the 'black box' problem often associated with deep learning in highly regulated fields like drug development.

What stage are BullFrog AI's drug programs currently in?

The company's most advanced program is for Glioblastoma (bf-222/bf-223), which is shown on slide 13 as having completed Phase 1 and moving toward a 'Partner' phase for Phase 2. Other programs, including those for Liver Cancer and Morbid Obesity, are in the discovery or preclinical stages, with several marked as 'planned' rather than active.

Who are the company's primary research partners?

BullFrog AI highlights several prestigious academic and research collaborators. Slide 13 lists The Johns Hopkins University, The George Washington University, and JCVI as collaborators for specific drug programs. Additionally, slide 16 emphasizes a relationship with the Lieber Institute for Brain Development (LIBD) for neuropsychiatric research.

How does the company justify the market need for its AI?

Slide 16 points to high failure rates in drug development and the extreme complexity of the human brain compared to animal models. It cites a 2023 Deloitte report stating that 1 in 8 people have a neuropsychiatric disorder, representing a $100 billion market that is expected to double by 2028, creating a massive tailwind for more efficient discovery tools.

Does the deck include a specific funding ask or valuation?

No. As a publicly traded company (NASDAQ: BFRG), this deck serves as a general investor presentation rather than a private seed or Series A pitch. It omits a specific 'ask' slide, valuation metrics, or a detailed breakdown of how new capital will be deployed, which are standard in private fundraising decks.

BullFrog AI Pitch Deck (2023): 21-Slide Breakdown

See all 21 slides of the BullFrog AI pitch deck — a 2023 deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

BullFrog AI (NASDAQ: BFRG) positions itself as a next-generation AI drug discovery company focused on reducing the high failure rates of clinical trials. The deck emphasizes the 'bfLEAP' platform's ability to handle incomplete, multi-modal data to identify 'clusters of factors' that predict patient response, specifically showcased through a schizophrenia trial collaboration with the Lieber Institute. While the company holds exclusive rights to several early-stage programs, including a Phase 2-ready glioblastoma candidate, the deck is heavily weighted toward technical capabilities and team ped…

Key takeaways

The company is publicly traded on NASDAQ under the ticker BFRG (Slide 1).
The proprietary platform, bfLEAP, is touted for its ability to generate predictions from incomplete data and its 'no code' scalability (Slide 7).
A key technical differentiator is 'Explainable AI,' which aims to provide transparency in how the model reaches its conclusions (Slide 7).
The company showcases a multivariate signature for schizophrenia, identifying genetic variants and physiological biomarkers in partnership with LIBD (Slide 10).
BullFrog AI holds exclusive rights to a Glioblastoma program (bf-222/bf-223) currently at the Phase 1/Phase 2 transition (Slide 13).
The pipeline includes early-stage 'planned' programs for Liver Cancer, Morbid Obesity, NASH, and NAFLD (Slide 13).
The neuropsychiatric market is cited as a $100 billion opportunity, projected to reach $200 billion by 2028 (Slide 16).
Founder and CEO Vin Singh previously co-founded MaxCyte Inc., which reached a ~$1B market cap (Slide 19).

Executive Summary and Brand Positioning

Slide 1: Title Slide

The deck opens with a high-concept visual featuring a geometric frog jumping through a portal, accompanied by the tagline 'Leap into the future of drug development.' It establishes the company as an AI-first entity, specifically mentioning the 'Maxim Emerging Growth in AI' presentation dated September 26, 2023. The NASDAQ ticker 'BFRG' is clearly displayed in the bottom right corner, signaling the company's public status immediately.

Slide 2: Mission Statement

This slide provides a concise value proposition: 'Using AI to accelerate the process of drug development and clinical testing, leading to effective treatments faster.' The layout is simple, placing the text in a centered box against a background of DNA and molecular imagery. It defines the company's role as a bridge between technology and clinical outcomes.

The Technology Platform

Slide 7: What makes BullFrog AI special?

This slide lists six core technical advantages of the 'bfLEAP' platform. These include: 1. Feature selection, 2. Predictions from incomplete data, 3. Scale with no code, 4. Multimodal data, 5. Disease Agnostic, and 6. Explainable AI. The inclusion of 'Explainable AI' is a strategic choice, as it addresses a common criticism of AI in healthcare—that models are often uninterpretable. The 'no code' mention suggests an emphasis on operational efficiency and accessibility for non-technical researchers.

Slide 10: Clusters of Factors to Predict Response

This is a highly technical slide demonstrating a case study in Schizophrenia. It features a complex network graph showing 'Clusters of Factors' used to predict patient response. The legend identifies Genetic Variants (SNPs), Physiological Biomarkers (Drug Clearance), Categorical Correlates (e.g., CT site), and Outliers. The slide credits the Lieber Institute for Brain Development (LIBD). This serves as proof-of-concept for the platform's ability to handle multi-variate signatures in complex neurological conditions.

Pipeline and Market Opportunity

Slide 13: World-wide Exclusive Rights

The pipeline slide is a standard but essential component of a biotech deck. It lists six programs. The lead candidate, bf-222/bf-223 for Glioblastoma, is a 'repurposed small molecule' that has progressed through Phase 1. The slide indicates a 'PARTNER' status for Phase 2. Other programs for Liver Cancer, Morbid Obesity, NASH, and NAFLD are in the discovery phase and utilize siRNA. A Colorectal Cancer program involving an Oncolytic Virus is listed as a co-development with JCVI. The chart clearly distinguishes between active progress and 'planned' stages using a color-coded legend.

Slide 16: Current Market Challenges

This slide builds the macro-economic case for the company. Citing a 2023 Deloitte report, it notes that the neuropsychiatric pharmaceutical market is currently $100 billion and projected to grow to $200 billion by 2028. It highlights the 'high failure rates in development' and the inability to perform brain tissue biopsies without harm as primary hurdles that BullFrog AI's technology is designed to solve. The slide also outlines a three-step process—Analyze, Identify, and Design/Screen—to reduce drug failure rates and increase repurposing insights.

Leadership and Expertise

Slide 19: Our Team

The team slide is exceptionally strong in terms of pedigree. CEO Vin Singh is noted as a co-founder of MaxCyte Inc., which achieved a ~$1B market cap. CFO Dane Saglio has experience with SEC compliance and multiple biotech mergers. The technical leadership includes Enrique Garcia-Rivera (VP of AI) with experience from the Broad Institute, and J.T. Koffenberger (CIO) with 30+ years in IT. The scientific side features Dr. Dave Recker (CMO), a former Senior VP at Takeda, and Dr. Kristin Bigos (Director CNS) from Johns Hopkins. This slide aims to de-risk the investment by showing that the leadership has 'been there before' in terms of both scientific discovery and corporate exits.

What BullFrog AI Does Well

The deck excels at establishing credibility through association. By prominently featuring logos and partnerships with Johns Hopkins, the Lieber Institute, and George Washington University, BullFrog AI positions itself as a serious player in the academic-industrial complex. The 'bfLEAP' platform is described with enough technical specificity (e.g., 'multimodal data,' 'explainable AI') to interest a specialist investor without becoming a white paper.

Furthermore, the pipeline slide (Slide 13) is honest about the stage of development. By marking several programs as 'planned,' the company avoids the trap of over-promising immediate clinical results for its entire portfolio, focusing instead on the Glioblastoma lead candidate as the primary value driver.

What is Missing from the Deck

As a teardown of the provided slides, several standard investor requirements are absent. There is no slide dedicated to the competitive landscape. In the crowded 'AI for Drug Discovery' space (populated by giants like Recursion or Exscientia), failing to differentiate against specific competitors is a notable omission.

Additionally, there is a lack of unit economics or specific financial data. While the market size is mentioned (Slide 16), the company does not provide its current burn rate, cash runway, or specific milestones tied to future funding. For a public company, this information is usually in the 10-K or 10-Q, but its absence in a 'pitch' format makes it harder for an investor to gauge immediate capital needs.

Founder Takeaways

Pedigree Matters: If your team has successful exits (like the MaxCyte $1B market cap mentioned on Slide 19), lead with it. It is the fastest way to build trust. · Visualizing Data: Slide 10 is a great example of how to show a 'black box' technology at work. The network graph makes the abstract concept of 'AI analysis' feel tangible and scientific. · Strategic Partnerships: Don't just list partners; show what they provide. BullFrog AI links specific institutions to specific drug candidates, which validates their pipeline. · Address the 'Black Box': If you are an AI company, explicitly mention 'Explainability.' Investors are increasingly wary of AI models that cannot be audited or understood by human scientists.

Frequently asked questions

What is the primary technology behind BullFrog AI?: The core technology is the bfLEAP platform, an analytical engine designed to process multi-modal data. According to slide 7, its key features include feature selection, the ability to make predictions from incomplete data, and 'Explainable AI.' This suggests the platform is built to overcome the 'black box' problem often associated with deep learning in highly regulated fields like drug development.
What stage are BullFrog AI's drug programs currently in?: The company's most advanced program is for Glioblastoma (bf-222/bf-223), which is shown on slide 13 as having completed Phase 1 and moving toward a 'Partner' phase for Phase 2. Other programs, including those for Liver Cancer and Morbid Obesity, are in the discovery or preclinical stages, with several marked as 'planned' rather than active.
Who are the company's primary research partners?: BullFrog AI highlights several prestigious academic and research collaborators. Slide 13 lists The Johns Hopkins University, The George Washington University, and JCVI as collaborators for specific drug programs. Additionally, slide 16 emphasizes a relationship with the Lieber Institute for Brain Development (LIBD) for neuropsychiatric research.
How does the company justify the market need for its AI?: Slide 16 points to high failure rates in drug development and the extreme complexity of the human brain compared to animal models. It cites a 2023 Deloitte report stating that 1 in 8 people have a neuropsychiatric disorder, representing a $100 billion market that is expected to double by 2028, creating a massive tailwind for more efficient discovery tools.
Does the deck include a specific funding ask or valuation?: No. As a publicly traded company (NASDAQ: BFRG), this deck serves as a general investor presentation rather than a private seed or Series A pitch. It omits a specific 'ask' slide, valuation metrics, or a detailed breakdown of how new capital will be deployed, which are standard in private fundraising decks.

Cover slide of the BullFrog AI pitch deck — Public (NASDAQ: BFRG) 2023 — BullFrog AI pitch deck, slide 1 (2023)

BullFrog AI pitch deck: the facts

Company: BullFrog AI
Year: 2023
Stage: Public (NASDAQ: BFRG)
Slides: 21
Sector: Biotechnology / AI Drug Discovery
Deck type: Investor Presentation
Outcome: Publicly Traded
Headquarters: United States

BullFrog AI pitch deck PDF

The full BullFrog AI deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the BullFrog AI Holdings, Inc. pitch deck was used for

This is BullFrog AI’s September 26, 2023 investor presentation used in connection with Maxim Group’s Emerging Growth in AI Virtual Tech Conference, where founder and CEO Vin Singh presented an overview of the company to public-market and institutional investors. The company had listed on Nasdaq under the symbol BFRG in February 2023 following an $8.4 million IPO of units priced at $6.50, and was using this deck to communicate its post-IPO strategy, AI platform, and pipeline rather than to market a specific private funding round. The deck highlights BullFrog AI’s bfLEAP AI/ML platform (licensed technology from Johns Hopkins Applied Physics Laboratory) and its early-stage internal drug development programs, alongside its positioning as a public micro-cap AI drug development platform.

Business model: BullFrog AI is a technology-enabled drug development company that uses its proprietary bfLEAP artificial intelligence and machine learning platform to analyze complex biological and clinical data, with the aim of improving the success of pharmaceutical and biologic development and enabling precision medicine.

Year: 2023
Founded: 2017
Founders: Vin Singh
Headquarters: Gaithersburg, Maryland, USA
Industry: Biotechnology / AI-driven drug development and precision medicine

Round: Initial public offering on the Nasdaq Capital Market (IPO). The September 2023 deck is a post-IPO investor presentation rather than a primary marketing document for a new private round.

Raised: BullFrog AI’s principal public fundraise around this deck was its initial public offering completed in February 2023, which raised approximately $8.4 million in gross proceeds from the sale of about 1.3 million units priced at $6.50 per unit.

Total funding: BullFrog AI raised approximately $8.4 million in gross proceeds from its initial public offering completed in February 2023.

Use of funds as presented: In connection with the IPO, BullFrog AI stated in its registration materials that it intended to use net proceeds to advance its AI platform and internal drug development programs, including bfLEAP deployment and preclinical/clinical development of its pipeline; the September 2023 deck functioned mainly to update investors on these efforts rather than re-define use of proceeds.

What happened after the BullFrog AI Holdings, Inc. deck

Following the use of the September 26, 2023 investor deck, BullFrog AI continued to operate as a Nasdaq-listed micro-cap AI-enabled drug development company, leveraging its bfLEAP platform and advancing early-stage programs such as BF-223, while maintaining its public listing and pursuing partnerships and development milestones.

Completed an initial public offering of approximately 1.3 million units at $6.50 per unit for gross proceeds of about $8
Entered into an exclusive worldwide licensing agreement with Johns Hopkins University Applied Physics Laboratory for pat
Reported positive preclinical data showing that BF-223, a novel mebendazole prodrug, demonstrated anti-cancer activity a

What the BullFrog AI Holdings, Inc. deck got right

AI platform anchored in exclusive Johns Hopkins APL technology. BullFrog AI’s core bfLEAP platform is based on patented technology from Johns Hopkins University Applied Physics Laboratory under an exclusive worldwide license, which provides a strong scientific pedigree and potential defensibility for its AI/ML approach to multimodal biological data.
Hybrid platform-plus-pipeline model with early preclinical validation. The company combines an AI/ML platform strategy with proprietary drug development, including BF-223, a novel mebendazole prodrug that has shown anti-cancer activity against glioblastoma in an animal model, giving investors exposure to both platform and asset value.
Validated by successful Nasdaq IPO. BullFrog AI successfully completed an $8.4 million Nasdaq IPO in February 2023, demonstrating capital markets access and providing a public currency and visibility for subsequent partnering and financing activities.
Institutional partnerships reinforce credibility. Management has secured notable partnerships and licensing deals, such as the exclusive worldwide license from Johns Hopkins APL for bfLEAP technology, supporting the company’s ability to collaborate with leading institutions in AI-driven drug development.
Strategic use of AI-focused investor events and channels. The September 2023 investor presentation was aligned with Maxim Group’s Emerging Growth in AI conference and publicly distributed via platforms like SlideShare, helping a newly listed micro-cap reach a broader base of AI-focused and retail investors.
Clear precision-medicine positioning for bfLEAP. BullFrog AI clearly positions its technology around precision medicine and patient stratification, an area of recognized unmet need in pharmaceutical R&D, which can resonate with both biotech specialists and generalist AI investors.

What could have been stronger

Limited visibility into clinical development timelines. The September 2023 investor materials and related public information emphasize platform capabilities and early preclinical data (e.g., BF-223 in an animal model for glioblastoma) but provide little detail on clinical-stage assets, trial timelines, or regulatory milestones, which may make it difficult for investors to assess near-term value inflection points.
Sparse disclosure on commercial traction and revenue. Available descriptions of the deck and related communications highlight the bfLEAP platform and institutional partnerships but provide limited quantitative information on revenue, signed commercial contracts, or backlog, leaving uncertainty about the current level of monetization and demand for the platform.
Dual platform-and-pipeline strategy not clearly capital-allocated. The company positions itself as both a platform provider and an internal drug developer, but public disclosures around the time of the deck provide limited detail on how capital and resources are prioritized between these activities, potentially complicating investors’ ability to model the business and understand the primary value driver.
Partnership economics and IP terms only briefly discussed. While the deck and associated investor communications reference technology derived from Johns Hopkins Applied Physics Laboratory and other partnerships, they provide relatively little detail on the economic terms, duration, and exclusivity conditions of these agreements, which are critical for assessing long-term competitive advantage and economics.

How an investor would read this deck

What draws attention

Platform differentiation of bfLEAP as a causal AI/ML system for multimodal biological data, derived from and exclusively licensed from Johns Hopkins Applied Physics Laboratory, which could provide a defensible technological edge in AI-driven drug development.
Early demonstration of internal drug candidates such as BF-223 for glioblastoma with preclinical anti-cancer activity in animal models, which offers potential drug-asset upside on top of platform revenues.
The company’s successful Nasdaq IPO in February 2023 raising approximately $8.4 million, showing some capital markets validation and providing a public listing for liquidity.
Management’s ability to form institutional partnerships (e.g., Johns Hopkins APL licensing agreement) and to position the story within thematic AI investor conferences like Maxim Group’s Emerging Growth in AI series.

Risks that stand out

BullFrog AI’s core drug programs were at preclinical or very early stages around the time of the deck, so investors face typical biotech development risks, including the possibility that candidates such as BF-223 fail in further preclinical or clinical testing despite promising initial animal data.
The company’s commercial traction and revenue base for its AI platform are not extensively detailed in available investor materials, exposing investors to uncertainty about the speed and scale at which bfLEAP can be monetized.
BullFrog AI depends on licensed technology from Johns Hopkins Applied Physics Laboratory for bfLEAP, which introduces counterparty and licensing risk, including potential limitations on fields of use or future renegotiation of terms.
As a small-cap public company that raised $8.4 million in its IPO, BullFrog AI may need additional capital to advance its pipeline through clinical development and to scale platform commercialization, creating financing and dilution risk for shareholders.

Questions this deck invites

How is BullFrog AI balancing investment between monetizing bfLEAP as a platform (through partnerships and services) versus funding internal drug development programs, and what are the expected economics and margins of each segment?
What are the detailed terms (royalties, milestones, fields of use, and duration) of the license agreement with Johns Hopkins Applied Physics Laboratory for the technology underlying bfLEAP, and how do these terms impact BullFrog AI’s long-t
What is the planned clinical development pathway, regulatory strategy, and expected timeline to first-in-human studies for lead candidates such as BF-223, and what capital will be required to reach meaningful clinical readouts?
What current or near-term commercial engagements (paid pilots, contracts, or collaborations) are in place for bfLEAP with pharmaceutical, biotech, or research institutions, and what evidence exists of recurring revenue or scalable demand fo
How does BullFrog AI’s AI/ML approach, performance, and data access compare quantitatively with other AI-enabled drug discovery and development companies, and what proprietary datasets or algorithms confer a durable competitive advantage?

What founders can take from the BullFrog AI Holdings, Inc. deck

A public-market investor deck for a newly public micro-cap like BullFrog AI often emphasizes clarification of the post-IPO strategy, platform foundations, and pipeline rationale rather than a specific private round ask, reflecting that the primary audience is ongoing and prospective public investors
Anchoring an AI biotech story in a credible academic or institutional partnership—in this case, an exclusive licensing agreement with Johns Hopkins Applied Physics Laboratory for the patented technology powering bfLEAP—can materially strengthen the perceived defensibility of the platform.
Combining an AI platform narrative with specific internal drug candidates (such as BF-223 for glioblastoma) allows a company to show both enabling-technology value and potential high-upside asset value, although it also requires careful explanation of capital allocation and strategy.
Aligning an investor deck with a high-visibility thematic conference (Maxim’s Emerging Growth in AI) and making it available on public platforms helps broaden awareness among retail and small institutional investors for a newly listed Nasdaq micro-cap.
Highlighting clear, concrete milestones (such as completing an IPO, signing a major licensing agreement, or generating positive preclinical data) can help an early-stage AI drug development company establish credibility despite limited clinical or revenue history.
Positioning an AI drug development platform around precision medicine and patient stratification (as BullFrog AI does with bfLEAP) taps into a widely understood unmet need in pharma R&D and can make the technical value proposition more intuitive to generalist investors.

BullFrog AI Holdings, Inc. pitch deck: common questions

What does BullFrog AI do?

BullFrog AI Holdings, Inc. (Nasdaq: BFRG, BFRGW) is a technology-enabled drug development company that uses its proprietary bfLEAP artificial intelligence and machine learning platform to analyze complex biological and clinical data, with the goal of enabling precision medicine and improving the success rate of pharmaceutical and biologic development.

When did BullFrog AI go public and how much did it raise?

BullFrog AI completed its initial public offering in February 2023, offering approximately 1.3 million units at $6.50 per unit for gross proceeds of about $8.4 million, and its common stock and tradeable warrants began trading on the Nasdaq Capital Market on February 14, 2023 under the symbols BFRG and BFRGW, respectively.

What is BullFrog AI’s bfLEAP platform?

The bfLEAP platform is an analytical AI/ML system derived from technology developed at the Johns Hopkins University Applied Physics Laboratory and licensed exclusively by BullFrog AI; it is designed to analyze multimodal biological and clinical data, with the intent of identifying predictive relationships and subpopulations to support drug development and precision medicine.

What is the context of BullFrog AI’s September 2023 investor deck?

The September 26, 2023 investor deck was used as part of BullFrog AI’s presentation at Maxim Group’s Emerging Growth in AI virtual tech conference, where CEO Vin Singh provided a company overview to investors; the slides on SlideShare correspond to this event and are positioned as a public-market investor presentation rather than a private fundraising pitch.

What drug programs or pipeline does BullFrog AI highlight?

As of 2023–2024 disclosures, BullFrog AI’s pipeline includes at least one proprietary glioblastoma candidate (BF-223, a novel prodrug of mebendazole that has shown anti-cancer activity in an animal model) and additional early-stage internal programs, supported by its bfLEAP AI platform and collaborations with research institutions.

Sources

Funding and outcome facts on this page were researched on 2026-08-21 from the pages below.

Related fundraising guides (24)

Decks from the same year (1)

2023 pitch deck examples

Decks from the same region (1)

US pitch deck examples

Browse companies alphabetically (1)

Pitch decks from companies starting with B

More pitch deck teardowns (16)

Recently published pitch deck teardowns (12)

Fundraising library · Pitch deck examples · Investor directory · Founder database